Plasma Protease C1-Inhibitor Market Expected to Grow at 14.1% CAGR Through 2029: Industry Forecast

 Get 20% Off Market Intelligence Reports With Code ONLINE20 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Expected Market Growth Rate for the Plasma Protease C1-Inhibitor Market?
 The plasma protease c1-inhibitor market size has grown rapidly in recent years. It will grow from $3.37 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to increasing prevalence of hereditary angioedema, growing awareness about rare genetic disorders, increasing demand for plasma-derived biologics, growing diagnostic rates for C1-inhibitor deficiency, and increasing adoption of replacement therapy in emergency care.
 
 The plasma protease c1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to growing focus on personalized medicine, increasing pipeline developments for C1-inhibitor therapies in clinical trials, growing demand for prophylactic treatment options, rising availability of home-based C1-inhibitor infusion therapies, and increasing awareness of C1-inhibitor deficiencies in surgical settings. Major trends in the forecast period include developing orphan drug applications, developing low-immunogenic variants, integration of genomic tools, integration into telemedicine platforms, and innovation in long-acting C1-inhibitors.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24659&type=smp
  
 Which Major Growth Drivers Will Influence the Plasma Protease C1-Inhibitor Market by 2029?
 The growing investment in rare diseases is expected to propel the growth of the plasma protease C1-inhibitor market going forward. A rare disease is a health condition that affects a small percentage of the population, typically fewer than 1 in 2,000 people. These conditions are often chronic and progressive and can be life-threatening or disabling. Investment in rare diseases is primarily due to the growing recognition of unmet medical needs and the potential for high returns through regulatory incentives such as orphan drug designation, market exclusivity, and reduced development costs. Investment in rare diseases drives the development of plasma protease C1-inhibitors by funding research and innovation to address hereditary angioedema and other rare conditions where C1-inhibitor deficiencies cause severe symptoms, thus accelerating the availability of targeted therapies. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, marking a 307% increase compared to the $1.8 billion raised in the same period in 2023. Therefore, the growing investment in rare diseases is driving the growth of the plasma protease C1-inhibitor market.
 
 How Is the Plasma Protease C1-Inhibitor Market Segmented?
 The plasma protease c1-inhibitor market covered in this report is segmented — 
 
 1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist
 2) By Dosage Form: Lyphophlised, Injectables
 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
 
 Subsegments:
 1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor
 2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor
 3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor
 4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor
 5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist
 
 What Are the Key Trends Shaping the Plasma Protease C1-Inhibitor Market?
 Major companies operating in the plasma protease C1-inhibitor market are focusing on developing advanced products, such as injectable prescription medicines, to ensure fast, effective relief for hereditary angioedema and improve treatment outcomes. Injectable prescription medicines refer to drugs administered by injection that help restore or replace plasma protease C1-inhibitor to regulate inflammation and prevent swelling attacks. For instance, in December 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, launched CINRYZE in India. CINRYZE is the first injectable FDA-approved C1 esterase inhibitor for prophylactic treatment in patients aged six years and older. It effectively reduces the frequency, severity, and duration of hereditary angioedema (HAE) attacks by increasing plasma levels of C1-INH, which helps prevent excess bradykinin production and controls the swelling associated with the condition.
 
 Which Organizations Are Key Contributors to the Plasma Protease C1-Inhibitor Market?
 Major companies operating in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V., Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, Lev Pharmaceuticals. 
 
 Get the full plasma protease c1-inhibitor market report here:
 https://www.thebusinessresearchcompany.com/report/plasma-protease-c1-inhibitor-global-market-report
 
 What Are the Regional Market Share Projections for the Plasma Protease C1-Inhibitor Market?
 North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protease c1-inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company